A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab in Participants With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2025-08-23
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of
BMS-986340 as monotherapy and in combination with nivolumab in participants with advanced
solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with
advanced solid tumors.